1. Brickyard Bancorp, Inc., Northbrook, Illinois (in formation); to become a bank holding company by acquiring 100 percent of the voting shares of Sysco Financial, Inc., Lincolnwood, Illinois, and thereby indirectly acquire Brickyard Bank, Lincolnwood, Illinois.

2. FirstBank of Illinois Co., Springfield, Illinois; to acquire 100 percent of the voting shares of BankCentral Corporation, Mattoon, Illinois, and thereby indirectly acquire Central National Bank of Mattoon, Mattoon, Illinois.

Board of Governors of the Federal Reserve System, January 21, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–1815 Filed 1–24–97; 8:45 am]

BILLING CODE 6210–01–F

Change in Bank Control Notices; Formations of, Acquisitions by, and Mergers of Bank Holding Companies; Correction

This notice corrects a notice (FR Doc. 97-368) published on page 1118 of the issue for Wednesday, January 8, 1997.

Under the Federal Reserve Bank of New York heading, the entry for Toronto-Dominion Bank, Toronto, Canada, and Waterhouse Investor Services, Inc., New York, New York, is revised to read as follows:

A. Federal Reserve Bank of New York (Christopher J. McCurdy, Senior Vice President) 33 Liberty Street, New York, New York 10045-0001:

1. The Toronto-Dominion Bank, Toronto, Canada, and its wholly-owned subsidiary, Waterhouse Investor Services, Inc., New York, New York; to acquire 50 percent of the voting shares of Marketware International, Inc., Holmdel, New Jersey (''Company''), and thereby develop and sell computer software products to facilitate the purchase and sale of securities by customers using personal computers, as well as other financial software products, pursuant to § 225.25(b)(7) of the Board's Regulation Y. *Company* would, *inter alia*, provide software to permit customers to place ''buy'' or ''sell'' orders with Waterhouse Securities, Inc., an affiliated broker-dealer, over the non-proprietary computer network known as the Internet. *Company* also would provide incidental software maintenance and product support services. *Company* proposes to conduct the proposed activities nationwide and in Canada.

Comments on this application must be received by February 7, 1997.

Board of Governors of the Federal Reserve System, January 21, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–1816 Filed 1–24–97; 8:45 am]

BILLING CODE 6210–01–F

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System, Federal Register Citation of Previous Announcement: 62 FR 3513, January 23, 1997.

PREVIOUSLY ANNOUNCED TIME AND DATE OF THE MEETING: 11:00 a.m., Monday, January 27, 1997.

CHANGES IN THE MEETING: Addition of the following closed item(s) to the meeting: Guidance on international cooperation.

CONTACT PERSON FOR MORE INFORMATION: Mr. Joseph R. Coyne, Assistant to the Board; (202) 452–3204.

Dated: January 23, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–2097 Filed 1–23–97; 3:28 pm]

BILLING CODE 6210–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary; Notice of Interest Rate on Overdue Debts

Section 30.13 of the Department of Health and Human Services' claims collection regulations (45 CFR Part 30) provides that the Secretary shall charge an annual rate of interest as fixed by the Secretary of the Treasury after taking into consideration private consumer rates of interest prevailing on the date that HHS becomes entitled to recovery. The rate generally cannot be lower than the Department of Treasury's current value of funds rate or the applicable rate determined from the ''Schedule of Certified Interest Rates with Range of Maturities.'' This rate may be revised quarterly by the Secretary of the Treasury and shall be published quarterly by the Department of Health and Human Services in the Federal Register.

The Secretary of the Treasury has certified a rate of 13 5/8% for the quarter ended December 31, 1996. This interest rate will remain in effect until such time as the Secretary of the Treasury notifies HHS of any change.

Dated: January 16, 1997.

George Strader,

Deputy Assistant Secretary, Finance.

[FR Doc. 97–1850 Filed 1–24–97; 8:45 am]

BILLING CODE 4150–04–M

National Institutes of Health

Statement of Organization, Functions, and Delegations of Authority

Part N, National Institutes of Health, of the Statement of Organization, Functions and Delegations of Authority for the Department of Health and Human Services (40 FR 22859, May 27, 1975, as amended most recently at 61 FR 54451, October 18, 1996, and redesignated from Part HN as Part N at 60 FR 56605, November 9, 1995) is amended, as set forth below to rename the National Center for Human Genome Research (N4, formerly HN4) to the National Human Genome Research Institute (NHGRI) and to amend its functional statement. Designating the Center as an Institute will enhance the organization's image as an Institute will enhance the organization's image as an NIH focal point for studying and understanding human genetic disease and allow the NHGRI to operate under the same legislative authorities as the other NIH research institutes.

Section N–B, Organizational and Functions, under the heading National Center for Human Genome Research (N4, formerly HN4), is revised as follows:

National Human Genome Research Institute (N4, formerly HN4). (1) Provides leadership for and formulates research goals and long-range plans to accomplish the mission of the Human Genome Project, including the study of the ethical, legal, and social implications of human genome research; (2) fosters, conducts, supports, and administers research and research training programs in human genome research by means of grants, contracts, cooperative agreements, and individual and institutional research training awards; (3) provides coordination for genome research, both nationally and internationally, and serves as a focal point within NIH and the Department of Health and Human Services for Federal interagency coordination, collaboration with industry and academia, and international cooperation; (4) plans, supports and administers intramural, collaborative and field research to study human genetic disease in its own laboratories, branches, and clinics; and (5) sponsors scientific meetings and symposia and collects and disseminates educational and informational materials related to human genome research to health professionals, the scientific community, industry, and the lay public.

This reorganization shall be effective January 14, 1997.

Dated: January 14, 1997.

Donna E. Shalala,

Secretary.

[FR Doc. 97–1849 Filed 1–24–97; 8:45 am]

BILLING CODE 4140–01–M

Administration for Children and Families

Submission for OMB Review; Comment Request

Title: Child Care Biannual Aggregate Report.

OMB No.: New Collection.

Description: This legislatively mandated report collects program and participant's data on all children and families receiving direct CCDF services. Aggregate data will be collected and will be used to determine the scope, type, and methods of child care delivery, and to provide a report to Congress.

Respondents: State governments, Guam, Virgin Islands, Puerto Rico and the District of Columbia.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
ACF–800	54	2	40	4,320

Estimated Total Annual Burden Hours: 4,320

Additional Information: Copies of the proposed collection may be obtained by writing to The Administration for Children and Families, Office of Information Services, Division of Information Resource Management Services, 370 L'Enfant Promenade, S.W., Washington, D.C. 20447, Attn: ACF Reports Clearance Officer.

OMB Comment

OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the Federal Register. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, 725 17th Street, N.W., Washington, D.C. 20503, Attn: Ms. Wendy Taylor.

Dated: January 21, 1997.

Douglas J. Godesky,

Reports Clearance Officer.

[FR Doc. 97–1851 Filed 1–24–97; 8:45 am]

BILLING CODE 4184–01–M

Food and Drug Administration

[Docket No. 96M–0456]

Home Access Health Corp.; Premarket Approval of the Home Access® HIV–1 Test System

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application by Home Access Health Corp. (HAHC), Hoffman Estates, IL, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of the Home Access® HIV–1 Test System. After reviewing the recommendation of the Blood Products Advisory Committee (BPAC), FDA's Center for Biologics Evaluation and Research (CBER) notified the applicant, by letter of July 22, 1996, of the approval of the application.

DATES: Petitions for administrative review by February 26, 1997.

ADDRESSES: Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Sukza Hwangbo, Center for Biologics Evaluation and Research (HFM–380), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–827–3524.

SUPPLEMENTARY INFORMATION: On June 1, 1995, HAHC, Hoffman Estates, IL 60195–5200, submitted to CBER an application for premarket approval of the Home Access® HIV–1 Test System. This product is intended for self-use by individuals who wish to obtain anonymous human immunodeficiency virus Type 1 (HIV–1) testing and counseling. The HIV–1 assay kits approved for use in the Home Access® HIV–1 Test System are: (1) The Vironostika HIV–1 Microelisa System® manufactured by Organon Teknika Corp.; (2) the Genetic Systems LAV EIA HIV–1 enzyme immunoassay (EIA) manufactured by Genetic Systems; and (3) the Fluorognost® HIV–1 immunoflourescence assay (IFA) manufactured by Waldheim Pharmazuetika. The HAHC testing service consists of: (1) The Home Access® HIV–1 Home Collection Kit; (2) Client*trak*™ (Interactive Voice Response System, automated HIV/acquired immune deficiency syndrome (AIDS) educational announcement, and client database); (3) laboratory testing; and (4) counseling and referral services. Each collection kit contains: An instruction manual, an HIV/AIDS educational booklet in English and Spanish, a blood spot collection card precoded with a unique 11-digit Home Access® code number, two safety lancets, an alcohol wipe, a sterile gauze pad, a bandage, a foil return pouch containing a desiccant, a safety lancet disposal container, a shipping container, and a preaddressed and prepaid return envelope. The test procedure begins when the client activates a unique 11-digit code number by calling a toll-free telephone number. Clients use the kit to obtain samples of their own blood which is placed on the collection card that is precoded with the code number. The collection card is mailed to HAHC using the provided mailer. Upon receipt, the sample is analyzed using enzyme linked immunosorbent assays licensed for the detection of HIV–1 antibodies. Test results are available to the client from HAHC within 3 business days after shipment of the sample to the laboratory for the Express Kit and within 7 days for the Standard Kit. The service is recommended for use by individuals 18 years of age or older.

On June 22, 1994, CBER consulted BPAC, an FDA advisory committee, for their comments and recommendations regarding issues FDA should address when reviewing home collection testing kits for the detection of HIV and other serious or life-threatening medical conditions. BPAC commented that the benefits of an alternative means of accessing previously unreachable